Douglas Ball was a founder of ZBX Corporation now a wholly owned subsidiary of NOWDiagnostics, Inc. At its Toronto-based laboratory and manufacturing facility, novel diagnostic biomarkers are adapted to the proprietary AdexusDx analytical platform forming unique point-of-care tests that showcase the best of one-step, small sample volume, whole-blood testing technology.
ZBX’s development and manufacturing capability is certified under ISO 13485 in addition to a Medical Device Establishment License from the Therapeutic Products Directorate, Health Products and Food Branch of Health Canada.
In 1991, he co-founded the first Canadian biotech company to be listed on NASDAQ, National Markets. Under his management, many novel products have been successfully introduced into the market. Mr. Ball was Vice President – Leveraged Buyouts – at Citibank Canada and a Representative with the Bank of Nova Scotia, New York. Mr. Ball has BA in Economics and Commerce from Carleton University, Ottawa and a MA in Policy Analysis from the New School for Social Research, New York City.